Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Tekmira to Present at the 16th Annual BIO CEO & Investor Conference

Globe Newswire February 5, 2014

Tekmira Receives US$14.5 Million Milestone Payment

Globe Newswire January 21, 2014

Tekmira Doses First Subject in Human Clinical Trial of TKM-Ebola

Globe Newswire January 14, 2014

Five Star Equities Issues New Research Reports on NDLS, SODA, TKMR and WEN

Accesswire January 14, 2014

Tekmira Pharmaceuticals (T.TKM) jumps 27.9% on Monsanto option deal

Chris Parry January 13, 2014

Microcap Report: T.CSI, T.LAC. T.QMX down, T.OSK, T.ETX, T.E up

Stockhouse Editorial January 13, 2014

Tekmira Signs Development Agreement on Delivery Technology for Agricultural Applications

Globe Newswire January 13, 2014

Tekmira Announces Strategic Reorganization to Strengthen Leadership Team

Globe Newswire January 6, 2014

Tekmira Receives $5 Million Milestone Payment for Phase III Initiation of LNP-Enabled Patisiran (ALN-TTR02)

Globe Newswire December 16, 2013

Tekmira Provides Corporate Update and Announces Third Quarter 2013 Results

Globe Newswire November 13, 2013

Tekmira Announces New Preclinical Data from Anti-Viral Programs

Globe Newswire November 12, 2013

Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02)

Globe Newswire November 10, 2013

Tekmira Announces Closing of Underwriters' Full Over-Allotment Option

Globe Newswire November 1, 2013

Preclinical Data Presented at Scientific Symposium Demonstrates That mRNA is Efficiently Delivered Using Tekmira's LNP

Globe Newswire October 24, 2013

Tekmira Announces Completion of US$30 Million Public Offering of Common Stock

Globe Newswire October 22, 2013

IIROC Trade Resumption - Tekmira Pharmaceuticals Corporation

Newsfile October 17, 2013

IIROC Trade Resumption - TKM

Canada NewsWire October 17, 2013

Tekmira Prices Public Offering of Common Stock

Globe Newswire October 17, 2013

IIROC Trade Halt - Tekmira Pharmaceuticals Corporation

Newsfile October 17, 2013

IIROC Trading Halt - TKM

Canada NewsWire October 17, 2013